Detection and characterization of VIM-52, a new variant of VIM-1 from clinical isolate.
(2021) Antimicrobial Agents and Chemotherapy — Vol. 65, n° 11, p. e0266020 (2021)
Files
deBarsyMAntimicrobAgentsChemother2021.pdf
Open Access - Adobe PDF
- 529.23 KB
Details
- Authors
- Abstract
- Over the last two decades, antimicrobial resistance has become a global health problem. In Gram-negative bacteria, metallo-β-lactamases (MBLs), which inactivate virtually all β-lactams, increasingly contribute to this phenomenon. The aim of this study is to characterize VIM-52, a His224Arg variant of VIM-1, identified in a clinical isolate. VIM-52 conferred lower MICs to cefepime and ceftazidime as compared to VIM-1. These results were confirmed by steady state kinetic measurements, where VIM-52 yielded a lower activity towards ceftazidime and cefepime but not against carbapenems. Residue 224 is part of the L10 loop (residues 221-241), which borders the active site. As Arg 224 and Ser 228 are both playing an important and interrelated role in enzymatic activity, stability and substrate specificity for the MBLs, targeted mutagenesis at both positions were performed and further confirmed their crucial role for substrate specificity.
- Affiliations
Citations
de Barsy, M., Mercuri, P. S., Oueslati, S., Elisée, E., Huang, T.-D., Sacré, P., Iorga, B. I., Naas, T., Galleni, M., & Bogaerts, P. (2021). Detection and characterization of VIM-52, a new variant of VIM-1 from clinical isolate. Antimicrobial Agents and Chemotherapy, 65(11), e0266020. https://doi.org/10.1128/AAC.02660-20 (Original work published 2021)